NEW YORK, December 23, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Waters Corp. (NYSE: WAT), Cognex Corporation (NASDAQ: CGNX), Fluidigm Corporation (NASDAQ: FLDM), Cepheid (NASDAQ: CPHD), and Bio-Rad Laboratories, Inc. (NYSE: BIO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Waters Corp. Research Report
On December 18, 2013, Waters Corp. (Waters) announced that its ACQUITY QDa Detector received recognition as one of the top innovations of 2013 by The Analytical Scientist magazine. According to the Company, the ACQUITY QDa Detector is a small, easy-to-use and affordable mass detector that brings high-quality mass spectral information to chromatographic separations, and was first introduced on October 7, 2013. Art Caputo, President, Waters Division, commented, "The development of the ACQUITY QDa Detector is the realization of a vision that started 20 years ago when we foresaw a day when chromatography and mass spectrometry technologies could be blended together to give every analytical scientist access to mass spectral data regardless of their previous experience with mass spectrometry." The Full Research Report on Waters Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cognex Corporation Research Report
On December 12, 2013, Cognex Corp. (Cognex) announced the launch of Cognex Tire Solutions, a suite of products designed to solve barcode and low-contrast embossed character reading challenges for tire manufacturers. According to the Company, Cognex Connect communications suite also makes it easy to integrate the Cognex Tire Solutions with factory networks. The Company reported that Cognex Tire Solutions are common stocked products backed by dedicated support networks that provide expedited product delivery. The Full Research Report on Cognex Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Fluidigm Corporation Research Report
On December 18, 2013, Fluidigm Corp. (Fluidigm) rose 14.04% to end the day at $36.06 compared to the previous day's closing price at $31.62. The Company's stock grew 12.48% over the past three trading days, compared to the Dow Jones Industrial Average which went up 2.62% over the same trading period. The Full Research Report on Fluidigm Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cepheid Research Report
On December 16, 2013, Cepheid (Cepheid) announced the appointment of Mr. James (Jim) Post as the Company's Executive Vice President of North American Commercial Operations, effective immediately. "Jim brings almost 20 years of performance-oriented medical technology sales leadership to Cepheid, with a wealth of experience spanning hospital and point-of care diagnostics," said John Bishop, Cepheid's Chairman and CEO. Bishop added, "I feel confident that Jim is the right leader to extend our placement lead and drive continued adoption of our rapidly growing Xpert test menu." Mr. Post joins Cepheid from Alere, Inc., where he most recently served as Global President of Acute Care. The Full Research Report on Cepheid - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Bio-Rad Laboratories, Inc. Research Report
On December 10, 2013, Bio-Rad Laboratories Inc. (Bio Rad) announced the appointment of Robert M. Malchione to the Company's Board of Directors, effective January 1, 2014. "We are pleased to have Robert join our Board," said Norman Schwartz, Bio Rad President and CEO. "His many years of experience working with large, global operations in a variety of areas will be a valuable addition to Bio Rad." Bio Rad informed that Mr. Malchione previously served as Senior Vice President, Corporate Strategy and Technology at Avery Dennison Corp., from 2000 to 2011. The Full Research Report on Bio-Rad Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved